Gut Microbiota and Environment in Coronary Artery Disease

Abstract

In recent years, studies evaluated the associations between coronary artery disease (CAD) and fecal gut microbiota composition. This opens new perspectives on therapeutic strategies to prevent CAD representing the leading cause of mortality in Western societies. We have conducted a review of the literature regarding the characteristics of the gut microbiota of CAD patients, its underlying mechanisms and their associations with pollution and the Western diet. The latest evidence confirms that an abnormal microbiota predisposes to the development of CAD and differs in composition compared to the microbiota of healthy patients; the results are, however, heterogeneous. The most studied underlying mechanisms involve the production of trimethylamine-N-oxide (TMAO), the synthesis of short-chain fatty acids (SCFAs) and the immune system activation mediated by lipopolysaccharides (LPS). Despite a large amount of available data, there is no evidence about the role of a specific type of gut microbiota in the risk of developing acute coronary syndrome (ACS). Moreover, no relationship has been assessed between the gut microbiota and the characteristics of coronary plaques in humans. However, a close association has been found between both pollution and the Western diet and gut microbiota and CAD. Further studies are needed to clarify the associations between gut microbiota, CAD, and ACS to find efficient therapeutic strategies.

Microbiota and Myopericarditis: The New Frontier in the Car-Diological Field to Prevent or Treat Inflammatory Cardiomyo-Pathies in COVID-19 Outbreak

“…Recent data demonstrated that COVID-19 patients have significant differences in gut microbiota composition and on the interaction between microbiota and host cells [ 73 ]. On the other side, as described in the introduction section, gastrointestinal dysbiosis can lead to cardiovascular diseases [ 2 , 3 , 77 ] and cardiovascular impairment can contribute to maintain gut microbiota dysbiosis [ 78 ]. In particular, many studies have described cases of patients with COVID-19 and inflammatory cardiomyopathies.…”

Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes

“…However, serious side effects have been reported in using statins, such as rhabdomyolysis, liver toxicity, and a higher risk for new-onset diabetes ( 5 ). Recent studies have also explored the role of gut microbiota and its derived metabolites (such as short-chain fatty acids [SCFAs], trimethylamine-N-oxide [TMAO], bile acids) in the pathogenesis of CAD ( 6 ), and a large body of evidence supports that the gut microbiota composition and its activity might play a role in atherosclerosis ( 7 ). The “gut-heart axis” via bidirectional communications between the gut and the heart together achieve cardiac homeostasis, and recent studies have shed new insight into the intricate mechanisms of CAD ( 8 ).…”

Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives

“…Although coronary artery disease and type 2 diabetes mellitus have also been proven to affect cardiac remodeling, these topics are beyond the scope of our review. To date, there is a huge amount of data, concerning the role of GMB in the pathogenesis and progression of type 2 diabetes mellitus and coronary heart disease (3971 and 312 publications over the last 5 years, respectively) [ 10 , 11 ]. To our opinion, these topics are well described elsewhere [ 12 , 13 ].…”